Epstein Secrets

Bloomberg (11/15, Levingston, 4.73M) reports Israel is "pushing forward with controversial plans to develop a Jewish enclave in a strategic area of East Jerusalem." On Sunday, the Israel Land Authority "solicited bids to build 1,257 apartments in the Givat Hamatos area, a project that was originally approved

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying

Bloomberg (11/15, Levingston, 4.73M) reports Israel is "pushing forward with controversial plans to develop a Jewish enclave in a strategic area of East Jerusalem." On Sunday, the Israel Land Authority "solicited bids to build 1,257 apartments in the Givat Hamatos area, a project that was originally approved

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying

Bloomberg (11/15, Levingston, 4.73M) reports Israel is "pushing forward with controversial plans to develop a Jewish enclave in a strategic area of East Jerusalem." On Sunday, the Israel Land Authority "solicited bids to build 1,257 apartments in the Givat Hamatos area, a project that was originally approved

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying